|
Thu, 12/15/2022 - 10:45 |
New drug combination offers hope for improved treatment of cervical cancer |
UTSouthwestern |
|
Thu, 12/15/2022 - 07:38 |
CASI Pharmaceuticals Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration |
CASI Pharmaceuticals |
|
Thu, 12/15/2022 - 03:41 |
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) |
DelMar Pharmace... |
|
Tue, 12/13/2022 - 11:24 |
Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis |
American Societ... |
|
Mon, 12/12/2022 - 09:17 |
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 |
Oxis Biotech |
|
Sat, 12/10/2022 - 10:18 |
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma |
Johnson and Johnson |
|
Wed, 11/30/2022 - 18:43 |
New Treatment Strategy Could Boost Efficacy of Immunotherapy in Patients With Solid Tumors |
Roswell Park Ca... |
|
Wed, 11/30/2022 - 12:06 |
Roswell Park, Genome Protection Inc. Team Discovers How Retrotransposons Fuel Drug Resistance in Tumors |
Roswell Park Ca... |
|
Wed, 11/23/2022 - 14:09 |
World first clinical trial in 'man's best friend' could unlock treatment breakthrough for kids with cancer |
UWA |
|
Fri, 11/18/2022 - 08:14 |
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting |
DelMar Pharmace... |
|
Thu, 11/17/2022 - 15:58 |
Ludwig Cancer Research study finds common, targetable mechanism tumors use to suppress immune responses |
Ludwig Cancer R... |
|
Sun, 11/13/2022 - 23:40 |
Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer |
Dana Farber |
|
Thu, 11/03/2022 - 10:23 |
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 |
Gilead Sciences |
|
Mon, 10/31/2022 - 00:00 |
Artificial Intelligence Approach May Help Identify Melanoma Survivors Who Face A High Risk of Cancer Recurrence |
Massachusetts G... |
|
Thu, 10/27/2022 - 14:29 |
Why immunotherapy works well for some cancer patients, but not others |
YaleUniversity |
|
Mon, 10/24/2022 - 21:48 |
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia |
BioAffinity Tec... |
|
Tue, 10/11/2022 - 13:33 |
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option |
Elevar Therapeutics |
|
Tue, 10/11/2022 - 12:20 |
Mayo Clinic Minute: What is CAR-T cell therapy? |
Mayo Clinic |
|
Wed, 10/05/2022 - 18:08 |
Cellectis to Present Pre-Clinical Data on TALEN-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting |
Cellectis |
|
Wed, 10/05/2022 - 02:51 |
GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer |
GlaxoSmithKline |
|
Mon, 10/03/2022 - 15:22 |
Tackling resistance to HIF2 drugs with an RNA-based therapy |
UTSouthwestern |
|
Fri, 09/30/2022 - 09:50 |
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma |
Gilead Sciences |
|
Fri, 09/30/2022 - 06:07 |
IMV Provides an Update on The VITALIZE Trial |
Immunovaccine |
|
Thu, 09/29/2022 - 18:37 |
Historical Housing Discrimination Adversely Associated with Contemporary Colon Cancer Care and Outcomes, Study Shows |
American Cancer... |
|
Wed, 09/28/2022 - 07:09 |
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma |
Roswell Park Ca... |
